Related Experiment Videos
[Spiramycin and the antibacterial therapy of mastitis]
Abstract:
The Minimum Inhibitory Concentrations (MIC) for 18 strains of staphylococci isolated from the national randomized mastitis surveys were determined. The antibiotics used were penicillin-G, cloxacillin and spiramycin. On the basis of these findings in addition to literature data concerning clinical efficacy trials it is concluded, that spiramycin is indicated for the treatment of persistent chronic udder infections caused by peniciline-G resistant strains of Staphylococcus aureus.
Insights
Spiramycin is effective for treating chronic mastitis in cows caused by penicillin-G resistant Staphylococcus aureus. Minimum Inhibitory Concentrations (MIC) testing guided this conclusion for antibiotic selection.
Area of Science:
- Veterinary Microbiology
- Antimicrobial Resistance
- Bacterial Infections
Context:
- Mastitis is a significant concern in dairy herds, impacting animal welfare and milk production.
- Staphylococcus aureus is a common pathogen causing persistent chronic udder infections.
- Penicillin-G resistance in Staphylococcus aureus necessitates alternative treatment strategies.
Purpose:
- To determine the Minimum Inhibitory Concentrations (MIC) of penicillin-G, cloxacillin, and spiramycin against Staphylococcus aureus strains from mastitis surveys.
- To evaluate the suitability of spiramycin for treating chronic mastitis caused by penicillin-G resistant Staphylococcus aureus.
- To synthesize in vitro susceptibility data with clinical efficacy literature.
Summary:
- Minimum Inhibitory Concentrations (MIC) were determined for 18 Staphylococcus aureus strains isolated from national mastitis surveys.
- Antibiotic susceptibility testing included penicillin-G, cloxacillin, and spiramycin.
- Spiramycin demonstrated efficacy against penicillin-G resistant strains, indicating its potential for treating chronic udder infections.
Impact:
- Provides evidence-based guidance for selecting effective antibiotics in bovine mastitis treatment.
- Highlights spiramycin as a viable therapeutic option for persistent chronic infections caused by resistant Staphylococcus aureus.
- Contributes to antimicrobial stewardship by identifying appropriate treatments for resistant mastitis pathogens.